Hypomagnesemia and incidence of osteoradionecrosis in patients with head and neck cancers.
chemoradiation
head and neck cancer
hypomagnesemia
osteoradionecrosis
platinum-based
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
20
05
2020
revised:
08
09
2020
accepted:
13
10
2020
pubmed:
24
10
2020
medline:
23
6
2021
entrez:
23
10
2020
Statut:
ppublish
Résumé
We aimed to determine whether hypomagnesemia predicts osteoradionecrosis development in patients with squamous cell carcinoma of the oropharynx and oral cavity who received platinum-based concurrent chemoradiation with or without induction therapy. We reviewed data from patients with head and neck cancers who had undergone chemoradiation with weekly cisplatin/carboplatin between January 1, 2010 and December 31, 2014 at our institution. Pathologic features, laboratory test results, disease stage, and social histories were recorded. The association between hypomagnesemia and osteoradionecrosis was analyzed controlling for known confounding factors. Hypomagnesemia during cancer treatment was associated with osteoradionecrosis development (HR = 2.72, P = .037) independent of total radiation dose (HR = 1.07, P = .260) and smoking history (HR = 2.05, P = .056) among the patients who received platinum-based induction chemotherapy followed by concurrent chemoradiation. Hypomagnesemia was predictive of the development of osteoradionecrosis in patients with cancers of the oropharynx and oral cavity receiving platinum-based induction followed by concurrent chemoradiation.
Sections du résumé
BACKGROUND
We aimed to determine whether hypomagnesemia predicts osteoradionecrosis development in patients with squamous cell carcinoma of the oropharynx and oral cavity who received platinum-based concurrent chemoradiation with or without induction therapy.
METHODS
We reviewed data from patients with head and neck cancers who had undergone chemoradiation with weekly cisplatin/carboplatin between January 1, 2010 and December 31, 2014 at our institution. Pathologic features, laboratory test results, disease stage, and social histories were recorded. The association between hypomagnesemia and osteoradionecrosis was analyzed controlling for known confounding factors.
RESULTS
Hypomagnesemia during cancer treatment was associated with osteoradionecrosis development (HR = 2.72, P = .037) independent of total radiation dose (HR = 1.07, P = .260) and smoking history (HR = 2.05, P = .056) among the patients who received platinum-based induction chemotherapy followed by concurrent chemoradiation.
CONCLUSIONS
Hypomagnesemia was predictive of the development of osteoradionecrosis in patients with cancers of the oropharynx and oral cavity receiving platinum-based induction followed by concurrent chemoradiation.
Identifiants
pubmed: 33094893
doi: 10.1002/hed.26510
pmc: PMC10359096
mid: NIHMS1915368
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
613-621Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE025248
Pays : United States
Organisme : NIDCR NIH HHS
ID : R56 DE025248
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
J Clin Endocrinol Metab. 1978 Oct;47(4):800-6
pubmed: 263326
Br J Cancer. 2001 Nov 30;85(11):1624-6
pubmed: 11742478
J Clin Endocrinol Metab. 1991 Nov;73(5):1067-72
pubmed: 1939521
Radiother Oncol. 2004 Nov;73(2):119-31
pubmed: 15542158
Am J Clin Nutr. 2014 Apr;99(4):926-33
pubmed: 24500155
Oral Oncol. 2017 Mar;66:75-80
pubmed: 28249651
Lancet Oncol. 2007 May;8(5):387-94
pubmed: 17466895
Contemp Clin Dent. 2018 Apr-Jun;9(2):242-248
pubmed: 29875568
Osteoporos Int. 2016 Apr;27(4):1389-1399
pubmed: 26556742
Magnes Res. 1999 Dec;12(4):257-67
pubmed: 10612083
Pediatr Nephrol. 1998 Sep;12(7):572-5
pubmed: 9761357
Radiother Oncol. 2017 Aug;124(2):232-239
pubmed: 28733053
Crit Rev Oncol Hematol. 2016 Jan;97:131-42
pubmed: 26318095
Clin Endocrinol (Oxf). 1976 May;5(3):209-24
pubmed: 182417
Am J Clin Oncol. 2018 Dec;41(12):1276-1280
pubmed: 29360644
Drug Saf. 2008;31(5):359-71
pubmed: 18422377
Sci Rep. 2016 Aug 08;6:29864
pubmed: 27499209
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):415-20
pubmed: 22795804
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):93-8
pubmed: 12504040
Am J Kidney Dis. 1986 Sep;8(3):164-9
pubmed: 3752072
J Clin Oncol. 2004 Dec 15;22(24):4867-8
pubmed: 15520050
J Clin Invest. 2007 Aug;117(8):2086-9
pubmed: 17671646
Eur J Epidemiol. 2017 Jul;32(7):593-603
pubmed: 28405867
J Am Coll Nutr. 2009 Apr;28(2):131-41
pubmed: 19828898
Ir J Med Sci. 2017 Feb;186(1):49-55
pubmed: 27339643
Bone. 2005 Aug;37(2):211-9
pubmed: 15923157